Gastric bypass surgery linked to bone-strength improvement in new study


By Reuters Staff

NEW YORK (Reuters Health) - Bone strength increases in the year after Roux-en-Y gastric bypass (RYGB) surgery in patients with and without type 2 diabetes, researchers from Norway report.

Previous studies reported reductions in areal bone mineral density (aBMD) and increases in bone turnover and fracture rate after RYGB surgery, but little is known about changes in bone material strength following surgery.

Dr. Ingvild K. Blom-Hogestol of Oslo University Hospital and colleagues evaluated the bone-material-strength index - a normalized measure of bone indentation depth - at the mid-shaft of the right tibia, aBMD and bone turnover markers in 34 morbidly obese individuals (13 with type 2 diabetes) one year after they underwent RYGB.

By then, participants had lost a mean 33.9 kg (28.3% of total body weight), the researchers report in Bone, online October 5. Mean vitamin D levels were unchanged after one year, but the number of participants with vitamin D deficiency had decreased from 11 preoperatively to seven.

Bone turnover markers increased significantly among patients with and without type 2 diabetes.

During this interval, aBMD decreased by 3.9% in the lumbar spine, 8.2% in the femoral neck, 11.6% in the total hip, and 9.4% in the total body, with no significant differences between participants with and without type 2 diabetes.

Despite these changes, bone material strength increased significantly from 78.1 preoperatively to 82.0 one year after RYGB surgery, an increase of 6.3%.

These increases in bone material strength did not differ significantly between patients with and without type 2 diabetes, but larger decreases in hemoglobin A1c among those with diabetes were associated with greater increases in bone material strength.

Dr. Blom-Hogestol did not respond to a request for comments.


Bone 2019.

Related Articles

Novartis CEO plans 80+ submissions for drug approvals through 2022

By Reuters Staff ZURICH (Reuters) - Novartis is planning more than 80 major submissions to regulators for drug approvals from 2020-2022 in the United States, Europe, Japan and China, Chief Executive Read More »

Biogen to make case to skeptics for its controversial Alzheimer's drug

By Deena Beasley and Julie Steenhuysen SAN DIEGO (Reuters) - Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Read More »

REFILE-Fewer bloodstream infections with fecal transplantation in recurrent C diff

(In para 5, changes (5/290) to (45/290), in story originally posted Nov 5.) By Reuters Staff NEW YORK (Reuters Health) - The incidence of bloodstream infections with recurrent Clostridioides difficile Read More »